Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Opdivo® (nivolumab) Plus Low-Dose Yervoy® (ipilimumab) as First-Line Treatment for Patients with Intermediate- and Poor-Risk Advanced Renal Cell Carcinoma

PRINCETON, N.J. - Bristol-Myers Squibb Company announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion recommending approval of the Opdivo (niv...

Priority Review Granted to BeiGene’s New Drug Applications for Zanubrutinib and Tislelizumab in China

CAMBRIDGE, Mass., and BEIJING, China - BeiGene, Ltd., a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of ...

$3mn Qatari Grant for WHO to Eradicate Tropical Diseases in Africa

The State of Qatar, represented by the Qatar Fund for Development (QFFD) signed yesterday a $3mn grant agreement with the World Health Organisation (WHO), on the sidelines of the World Innovation Summit for Health (WISH)...

panCELLa's Exclusive FailSafe™ Improves Cell Therapy Safety

TORONTO, Canada - panCELLa is proud to announce the publication of "Linking a cell division and a suicide gene to define and improve cell therapy safety" in the November 21st 2018 issue of Nature.Cell therapies hold enor...

Latest Results from the I-SPY 2 Trial at the EORTC-NCI-AACR Symposium Demonstrate Ability of MammaPrint® and BluePrint® to Predict Treatment Response in Breast Cancer Patients

IRVINE, Calif. and AMSTERDAM, Netherland - Agendia, Inc., a world leader in precision oncology, announced new data from the I-SPY 2 study, presented at the European Organization for Research and Treatment of Cancer (EORT...

Mallinckrodt's SpecGx LLC Reports on Outcome of FDA Joint Advisory Committee on Abuse-Deterrent, Immediate-Release Reformulation of Roxicodone® (Oxycodone Hydrochloride)

ST. LOUIS - SpecGx LLC (SpecGx), a subsidiary of Mallinckrodt plc that operates its Specialty Generics business, announced that, in a joint meeting, the U.S. Food and Drug Administration's (FDA's) Anesthetic and Analgesi...

Five Prime Therapeutics Initiates Patient Dosing in a Phase 1 Clinical Trial of FPT155, a First-in-Class CD80 Fusion Protein

SOUTH SAN FRANCISCO, Calif. - Five Prime Therapeutics, Inc., a biotechnology company discovering and developing innovative immuno-oncology protein therapeutics, announced it initiated patient dosing in a Phase 1 clinical...

Alnylam Presents Updated Phase 1/2 Open-Label Extension (OLE) Results for Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyria

CAMBRIDGE, Mass. - Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced that the Company presented updated results from the ongoing Phase 1/2 open-label extension (OLE) study of givosiran, an i...

First Patient Enrolled in Pivotal Clinical Phase 3 Study NEFIGARD with Lead Candidate Nefecon

STOCKHOLM-Calliditas Therapeutics AB (publ) ("Calliditas")  announced that the first patient has been enrolled in the company's pivotal clinical phase 3 study NEFIGARD in patients with IgA nephropathy (IgAN).The NEFIGARD...

CWRU-Led Study Triggers Change in WHO Treatment Guidelines for Lymphatic Filariasis

CLEVELAND, OH - Researchers from Case Western Reserve University School of Medicine have shown that a single "cocktail" of three pill-based anti-parasite medications is significantly more effective at killing microscopic...